ContentList volumes - List articles in this issue
A Reduced National Incidence of Anogenital Warts in Young Danish Men and Women after Introduction of a National Quadrivalent Human Papillomavirus Vaccination Programme for Young Women – An Ecological Study
In January 2009 the human papillomavirus (HPV) vaccine was included in the Danish childhood vaccination programme for girls aged 12 years. A catch-up programme for girls up to 16 years of age was started a couple of months earlier. Based on national register data, anogenital wart (AGW) incidences between January 2001 and December 2011 were estimated. We used χ2 analysis to identify significant trends in proportions of patients diagnosed with AGW in the period before and after inclusion of the HPV vaccine in the program. The development of chlamydia infections was included in this study as a proxy for possible behaviour changes that could affect the AGW incidence. Between 2008 and 2011, a 50% (95% CI 44–56) decrease in AGW incidence was seen among 15–19-year-old men (p = 0.041), from 5.2 to 2.6/1,000. Among women, a 67% (95% CI 63–72) decrease from 11.7 to 3.8/1,000 was seen (p < 0.0001). The decline in frequency of AGW in young Danish women seems to result from the high coverage of the HPV vaccination programme and young men probably benefit from herd immunity.
Niels Sandø, Kristian Kofoed, Claus Zachariae, Jan Fouchard
Disease prevention & local services, Danish Health and Medical Authority, DK-2300 Copenhagen, Denmark
References1. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S. Genital warts incidence and healthcare resource utilisation in Australia. Sex Transm Infect 2010; 86: 181–186.
2. Langley PC, White DJ, Drake SM. Patterns of treatment and resource utilization in the treatment of external genital warts in England and Wales. Int J STD AIDS 2004; 15: 473–478.
3. Pirotta M, Ung L, Stein A, Conway EL, Mast TC, Fairley CK, Garland S. The psychosocial burden of human papillomavirus related disease and screening interventions. Sex Transm Infect 2009; 85: 508–513.
4. Skaaby S, Kofoed K. Anogenital warts in Danish men who have sex with men. Int J STD AIDS 2011; 22: 214–217.
5. Aubin F, Prétet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008; 47: 610–615.
6. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999; 37: 3316–3322.
7. Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949–1957.
8. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341: c3493.
9. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–1943.
10. pro.medicin.dk. Ref Type: Online Source. [accessed Dec 1, 2012].
11. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593–4599.
12. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971; 47: 1–13.
13. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11: 39–44.
14. Leval A, Herweijer E, Arnheim-Dahlström L, Walum H, Frans E, Sparén P, Simard JF. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012; 206: 860–866.
15. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87: 544–547.
16. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499–502.
17. Unknown. [Public attitudes, knowledge and behavior in relation to sexuality, STIs and HIV.] 2004. Report in Danish. Available from: www.sst.dk/publ/Publ2004/Undersoeg_seksualitet_hovedrapp.pdf.
18. Palefsky JM. HPV infection in men. Dis Markers 2007; 23: 261–272.
19. Nyitray AG, Carvalho da Silva RJ, Baggio ML, Smith D, Abrahamsen M, Papenfuss M, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis 2011; 204: 1711–1722.
20. Jiang J, Cao N, Zhang J, Xia Q, Gong X, Xue H, et al. High prevalence of sexually transmitted diseases among men who have sex with men in Jiangsu Province, China. Sex Transm Dis 2006; 33: 118–123.